Carle Health’s Post

Learn how our client set their Phase II clinical trial up for success by gathering early insights from oncologists, nurses & patients through the Impetus InSite Platform®. Download our customer story to see how we're transforming clinical trials! https://hubs.la/Q02m_Q-h0 #ClinicalTrials #Innovation #PatientCentricTrials #PatientEngagement #OncologyInnovation

In research published in BMC Nursing underscores the critical importance of patient-centric approaches in healthcare. This insightful study reveals how enhanced patient engagement not only improves clinical outcomes but also enriches the quality of data. As we continually strive to place patient needs at the forefront, this article offers valuable insights and affirms the significance of what we do. Dive into the full study to see how shifting focus towards patient experiences lead to better outcomes. https://lnkd.in/e4Q6UAtC #PatientCare #DrivingChange #HealthcareInnovation

🌟 **Collaboration: The Heart of Oncology Pharmacy** 🌟 In today’s rapidly evolving healthcare landscape, the power of collaboration is more crucial than ever, particularly within the European Society of Oncology Pharmacy (ESOP). Together, we are not just a network of professionals; we are a unified force committed to enhancing patient care. Every day, pharmacists, physicians, nurses, and allied health professionals join forces, sharing knowledge, insights, and experiences. This multidisciplinary approach drives innovation and the creation of comprehensive treatment plans tailored to the unique needs of each patient. Our collaborative efforts not only improve our processes but also lead to better outcomes for those we serve. Let’s continue to inspire one another and push the boundaries of what is possible. Together, we can ensure that every patient receives the highest standard of care, guided by the latest advancements in oncology pharmacy. In unity, there is strength. In collaboration, there is hope. 💪💖 Klaus Meier Dirk Arnold Dr. Dégi László Csaba Fernand Sauer Adela Maghear Isabelle Borget Margaret Graham McDonald BSc (Hons) Tech Professor Alain Astier Christophe Bardin Robert Terkola Carien Van Der Merwe Sherif Kamal Marko Skelin M.Pharm PhD Mirjam Crul Kristjan Kongi Roman Goněc Fabrizio Festinese Patrícia Pereira Victoria Zapotochna #OncologyPharmacy #Collaboration #PatientCare #HealthcareInnovation #ESOP #ECOP6

✨ New Call for Manuscripts✨ The Clinical Journal of Oncology Nursing (CJON) invites manuscript submissions for an upcoming special issue focusing on interventional oncology (IO). We are seeking high-quality papers by February 1, 2025, that explore innovative practices, research, and insights within this dynamic field. We welcome submissions that contribute to the nursing advancement of IO, including through original evidence-based practice, case studies, reviews, or innovative practices. For more information, please contact either Evelyn P. Wempe, CJON supplement guest editor, at ewempe@med.miami.edu, or me, CJON editor, at CJONEditor@ons.org. Key topics of interest include: 🎯 Quality and safety: approaches to enhancing patient safety and treatment outcome in IO 🎯Patient experience: studies or case reports that focus on patient-centered care in IO, including patient satisfaction and quality of life 🎯IO program development: strategies for establishing, managing, and optimizing IO programs within healthcare institutions 🎯Clinician experience: insights into the experiences and challenges faced by clinicians working in IO, including training, burnout, and professional development 🎯Equity in IO: research addressing disparities in access to IO treatments and outcomes, with a focus on promoting equity in care #Scholarship #EBP #NurseAuthors #PeerReviewed #InterventionalOncology #OncologyNursing #CJON

One year ago I was a P4 student completing an ambulatory care rotation at LMH with Emily Prohaska, PharmD, BCACP, FAPhA. This rotation (and Emily because she's the best!) helped me realize my passion and interest in osteoporosis since it is so common but largely undiagnosed and undertreated. During my current PGY1 residency at Creighton University School of Pharmacy, I completed my first Grand Rounds presentation overviewing osteoporosis. I recently wrote a newsletter for PharMerica discussing diagnosis and treatment of osteoporosis, focusing on non-oral treatment options. My article link is attached below for anyone interested in reading more about this topic!

Exciting News! Mainstay Medical proudly announces the publication of clinical results comparing older and younger patients in a pooled analysis of three studies evaluating the safety and efficacy of ReActiv8 Restorative Neurostimulation. No significant differences were found, highlighting the therapy's consistent effectiveness across age groups. Jason Hannon, CEO of Mainstay Medical, stated: “High quality clinical evidence sets us apart in this industry. We study, learn, and demonstrate outcomes in patient populations before we suggest ReActiv8 is beneficial to a particular group of patients. This is how we partner with clinicians to deliver the best possible, and most durable, treatments for their patients. With these exciting results demonstrating the value of ReActiv8 across all studied age groups, we can now confidently support identification of older patients who are likely to benefit from the therapy. We look forward to continuing to partner with physicians to help chronic low back pain patients of all ages, and to growing the global body of peer-reviewed evidence supporting the ability of ReActiv8 to provide positive long-term outcomes.” View press release here → https://lnkd.in/es9U-A2p. #mainstaymedical #reactiv8 #multifidusdysfunction #chroniclowbackpain #restorativetherapy #thinkrestorative #restorativerevolution #lowbackpain #clbp #helpingpatients #patientfocus #puttingpatientsfirst Dr. Ardeshir Ardeshiri | Marco Amann | Simon Thomson | Christopher Gilligan, M.D.

Opportunity to publish in The Clinical Journal of Oncology Nursing (CJON) on the topic of interventional oncology!

Great news for our patients and families at #HDReach We couldn’t break it down any better than one of our own rockstars of a community member, Lauren! Check out the latest update from UniQure and what it means for the HD community 💙💙 #ReachforHope #cureHD #cureJHD #HDReach I am so incredibly excited to be sharing this update from #UniQure this morning! The 1st important point is this: "The FDA granted RMAT designation based on the potential of AMT-130 to address the major unmet medical need among patients with Huntington’s disease. The designation follows the FDA’s review of interim Phase I/II clinical data for AMT-130 announced in December 2023 and is based on an analysis comparing these 24-month clinical data to a non-concurrent criteria-matched natural history cohort." What this means: For the 1st time ever for HD, the FDA allowed the use of natural history as a comparison. This means that UniQure was able to use all the data collected through studies like ENROLL-HD, among others, as a type of control to compare and show whether their drug is helpful to participants. This is HUGE! This will allow UniQure to move faster with their clinical trial rather than having to spend several years (4+ years) seeing if the drug is doing what it's supposed to. THIS gives us some time back that we desperately need. And hopefully it means the FDA will allow the same thing in some other clinical trials in the future. THIS is a WIN for us all! Okay, 2nd point: “Importantly, RMAT designation allows for increased collaboration with the FDA to accelerate development, potentially facilitating earlier access for patients with life-threatening medical conditions." "A regenerative medicine therapy can be eligible for RMAT designation if it is intended to treat, modify, reverse or cure a serious condition, and if preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a condition." What this means: This designation opens the door for better collaboration with the FDA, for "fast track" programs and other ways to help speed up the clinical trial process. The only time the FDA gives this designation is because after reviewing the preliminary data, the FDA felt that it was significant and positive enough to get things moving MUCH faster in order to get this treatment to people. They see the potential of how this treatment can benefit us. Guys, I can't stress enough how wonderful this is for us, how monumental this step is for us. Let's make sure we let the FDA know that. 😊 Also, huge thanks to UniQure for working so hard on this. I'm so grateful to have them working so hard for us. #letsgetloudabouthd #dyingtolive #HuntingtonsDisease #raredisease #hdresearch #genetherapy

An inspiring but frustrating book Buried or Planted to read by Stephanie S. Abbott, MBA, CLSSBB, FACHE that captures her cancer survival journey with a great deal of POOR experiences in care, treatments, communication and compassion. Our healthcare CAN BE better than this and MUST BE. I challenge our various Boards of Medicine, Nursing, and essentially all colleges and certifying bodies relevant to healthcare to consider this book as part of their required reading. Stephanie’s experience and her life deserves improvement in our medical and compassionate treatment of each other. Do One Thing to make it better. Stephanie makes it easy for you at the end of each chapter. Compassion not only improves clinical QUALITY, motivates better patient self-care and drives REVENUE in healthcare organizations that excel in compassionate care.  What will YOU do?  https://lnkd.in/eaSUjV2p